Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DCGO Stock Forecast 2026-2027
$0.69
Current Price
$68.14M
Market Cap
Buy 3
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to DCGO Price Targets
+335.0%
To High Target of $3.00
+262.5%
To Median Target of $2.50
+45.0%
To Low Target of $1.00
DCGO Price Momentum
+30.2%
1 Week Change
+3.0%
1 Month Change
-67.3%
1 Year Change
-21.6%
Year-to-Date Change
-71.8%
From 52W High of $2.45
+40.5%
From 52W Low of $0.49
📊 TOP ANALYST CALLS
Did DCGO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if DocGo is one of their latest high-conviction picks.
Latest DCGO Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, DCGO has a neutral consensus with a median price target of $2.50 (ranging from $1.00 to $3.00). The overall analyst rating is Buy (7.7/10). Currently trading at $0.69, the median forecast implies a 262.5% upside. This outlook is supported by 3 Buy, 3 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DCGO Analyst Ratings
3
Buy
3
Hold
0
Sell
DCGO Price Target Range
Low
$1.00
Average
$2.50
High
$3.00
Current: $0.69
Latest DCGO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DCGO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 25, 2026 | Canaccord Genuity | Richard Close | Hold | Maintains | $1.00 |
| Mar 17, 2026 | Needham | Ryan MacDonald | Buy | Reiterates | $3.00 |
| Mar 17, 2026 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $3.00 |
| Mar 17, 2026 | Stifel | David Grossman | Buy | Maintains | $2.50 |
| Nov 12, 2025 | Canaccord Genuity | Richard Close | Hold | Maintains | $1.50 |
| Aug 21, 2025 | Canaccord Genuity | Richard Close | Hold | Maintains | $1.60 |
| May 12, 2025 | Canaccord Genuity | Richard Close | Hold | Downgrade | $1.45 |
| May 9, 2025 | Needham | Ryan MacDonald | Buy | Maintains | $3.00 |
| Apr 8, 2025 | Needham | Ryan MacDonald | Buy | Reiterates | $4.00 |
| Feb 28, 2025 | Stifel | David Grossman | Buy | Maintains | $5.50 |
| Feb 28, 2025 | Needham | Ryan MacDonald | Buy | Maintains | $4.00 |
| Jan 16, 2025 | Needham | Ryan MacDonald | Buy | Reiterates | $7.00 |
| Sep 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $5.00 |
| Aug 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $5.00 |
| Aug 8, 2024 | Needham | Ryan MacDonald | Buy | Reiterates | $7.00 |
| May 9, 2024 | Canaccord Genuity | Richard Close | Buy | Maintains | $5.00 |
| May 9, 2024 | BTIG | David Larsen | Buy | Maintains | $7.00 |
| May 9, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Maintains | $5.00 |
| May 9, 2024 | Needham | Ryan MacDonald | Buy | Maintains | $7.00 |
| Apr 30, 2024 | Stifel | David Grossman | Buy | Maintains | $6.50 |
DocGo Inc. (DCGO) Competitors
The following stocks are similar to DocGo based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DocGo Inc. (DCGO) Financial Data
DocGo Inc. has a market capitalization of $68.14M with a P/E ratio of 8.5x. The company generates $322.20M in trailing twelve-month revenue with a -56.6% profit margin.
Revenue growth is -38.0% quarter-over-quarter, while maintaining an operating margin of -43.3% and return on equity of -89.0%.
Valuation Metrics
Market Cap
$68.14M
Enterprise Value
$24.08M
P/E Ratio
8.5x
PEG Ratio
3.9x
Price/Sales
0.2x
Growth & Margins
Revenue Growth (YoY)
-38.0%
Gross Margin
+32.5%
Operating Margin
-43.3%
Net Margin
-56.6%
EPS Growth
-38.0%
Financial Health
Cash/Price Ratio
+74.9%
Current Ratio
2.3x
Debt/Equity
23.2x
ROE
-89.0%
ROA
-16.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
DocGo Inc. (DCGO) Business Model
About DocGo Inc.
What They Do
Provides mobile and integrated medical care solutions.
Business Model
DocGo Inc. operates by delivering non-emergency medical services directly to patients, leveraging technology to enhance healthcare delivery and access. The company generates revenue through its innovative services, which include real-time tracking of medical transportation and remote patient monitoring, thereby streamlining operations and improving patient convenience.
Additional Information
DocGo plays a vital role in supporting hospital systems and emergency services, particularly in underserved communities, by reducing the strain on traditional healthcare facilities. This approach not only improves healthcare accessibility but also contributes to the overall efficiency of medical service delivery.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
2,537
CEO
Mr. Lee Bienstock
Country
United States
IPO Year
2000
Website
docgo.comDocGo Inc. (DCGO) Latest News & Analysis
Latest News
Quick Summary
DocGo Inc. has been named one of the 2026 World's Most Ethical Companies® by Ethisphere, marking its first recognition in this category. It is one of four honorees in healthcare services.
Why It Matters
DocGo's recognition as one of the World's Most Ethical Companies enhances its reputation, potentially attracting more clients and investors, and may lead to increased stock value and market confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
DocGo Inc. (DCGO) held its Q4 2025 earnings call, providing updates on financial performance and strategic initiatives. Further details can be accessed in the full transcript.
Why It Matters
The Q4 2025 earnings call for DocGo Inc. provides insights into the company's financial performance, growth prospects, and strategic direction, influencing stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
DocGo Inc. (Nasdaq: DCGO) reported Q4 2025 revenue of $74.9 million, down from $120.8 million in Q4 2024, attributed to the wind-down of a specific service.
Why It Matters
DocGo's revenue drop signals operational challenges and market shifts, potentially impacting future growth and investor confidence. The wind-down of a major service could affect profitability.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
DocGo Inc. (DCGO) reported a quarterly loss of $0.53 per share, worse than the expected loss of $0.10, compared to earnings of $0.04 per share from the previous year.
Why It Matters
DocGo's larger-than-expected quarterly loss signals potential operational issues, impacting investor confidence and likely leading to a decline in share price.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Shareholders can contact the firm to discuss their rights and options at no cost. Legal fees are contingent, meaning no upfront payment is required.
Why It Matters
Shareholder engagement signals potential legal issues or disputes, which could impact company performance and stock value, affecting investor sentiment and decisions.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
DocGo Inc. (Nasdaq: DCGO) will announce Q4 and full-year 2025 financial results on March 16, 2025, after market close, followed by a conference call at 5:00 p.m. ET.
Why It Matters
DocGo's upcoming financial results and outlook conference call may influence stock performance, providing insights into growth and profitability that impact investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About DCGO Stock
What is DocGo Inc.'s (DCGO) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, DocGo Inc. (DCGO) has a median price target of $2.50. The highest price target is $3.00 and the lowest is $1.00.
Is DCGO stock a good investment in 2026?
According to current analyst ratings, DCGO has 3 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.69. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DCGO stock?
Wall Street analysts predict DCGO stock could reach $2.50 in the next 12 months. This represents a 262.5% increase from the current price of $0.69. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is DocGo Inc.'s business model?
DocGo Inc. operates by delivering non-emergency medical services directly to patients, leveraging technology to enhance healthcare delivery and access. The company generates revenue through its innovative services, which include real-time tracking of medical transportation and remote patient monitoring, thereby streamlining operations and improving patient convenience.
What is the highest forecasted price for DCGO DocGo Inc.?
The highest price target for DCGO is $3.00 from at , which represents a 335.0% increase from the current price of $0.69.
What is the lowest forecasted price for DCGO DocGo Inc.?
The lowest price target for DCGO is $1.00 from at , which represents a 45.0% increase from the current price of $0.69.
What is the overall DCGO consensus from analysts for DocGo Inc.?
The overall analyst consensus for DCGO is neutral. Out of 8 Wall Street analysts, 3 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $2.50.
How accurate are DCGO stock price projections?
Stock price projections, including those for DocGo Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 7:24 AM UTC